Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-12
SponsorIndizen Optical Technologies, S.L.U.

About this trial

The Goal of the study is to evaluate the rate of myopia progression with open ring myopia control spectacle lens designs compared to a commercial peripheral plus myopia control spectacle lens (CML) in European children with myopia. This is a prospective, randomized, bilateral wear, double masked, cross-over clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).

Group 2 - 60 participants will wear the Open Ring 1 (OR1) lens design. Group 3 - 60 participants will wear the Open Ring 2 (OR2) lens design. For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old. All groups will be required to wear spectacles for all waking hours for 12 months. After 12 months, the control group will continue wearing CML for a further 12 months; the Group 2 participants will continue wearing the OR1 lens for a further 12 months. The Group 3 participants will wear OR2 or OR3 (a modified design of OR2) based on their risk of myopia progression for a further 12 months

Eligibility criteria

Qualifiers

Be aged between 6 to 12 completed years (6 and 12 years inclusive), irrespective of gender.

For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old.

Be cycloplegic autorefraction spherical component -0.50 D to -6.00D, cylinder no more than -2.00D, and with a spherical equivalent greater than or equal to -6.00D.

Be accompanied by parents/guardians who can read and comprehend give informed consent as demonstrated by signing a record of informed consent.

Disqualifiers

A known allergy to, or a history of intolerance to cyclopentolate or topical anesthetics.

Had strabismus and/or amblyopia.

Cylinder more than -2.00D

Anisometropia greater than 1.50D spherical equivalent

Trial design

Treatments tested in this trial

  • myopia control lens

Treatment groups

No treatment groups listed

Sponsors and collaborators

Indizen Optical Technologies, S.L.U.

Lead sponsor

Hospital San Carlos, Madrid

Collaborator

University of Minho

Collaborator

University of Ulster

Collaborator